Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01937117 · ClinicalTrials.gov registry record · Phase 2

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Active
Registry status
Phase 2
Development phase
88
Enrollment target
10
Study locations

NCT01937117 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 88 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01937117, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
88 participants
Enrollment target
10
Study locations

Study Summary

This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Trastuzumab
  • DRUG Pertuzumab
  • PROCEDURE Positron emission tomography (PET)

Study Locations (10)

Texas

  • Baylor College of Medicine - Houston
  • The University of Texas MD Anderson Cancer Center - Houston

Alabama

  • University of Alabama Comprehensive Cancer Center - Birmingham

District of Columbia

  • Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital - Washington D.C.

Indiana

  • Indiana University Simon Cancer Center - Indianapolis

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Minnesota

  • Mayo Clinic - Rochester

North Carolina

  • Lineberger Comprehensive Cancer Center - Chapel Hill

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2014-01-30
Est. Completion 2026-06
Phase Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01937117

The ClinicalTrials.gov registry entry for NCT01937117 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Trastuzumab is the first listed.

NCT01937117 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, Alabama, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT01937117 about?

NCT01937117 is a clinical study titled "Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer". This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.

What is the current status of trial NCT01937117?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2014-01-30. Estimated completion is 2026-06.

What conditions does trial NCT01937117 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT01937117?

The interventions under investigation include: Trastuzumab (DRUG), Pertuzumab (DRUG), Positron emission tomography (PET) (PROCEDURE).

Who is sponsoring clinical trial NCT01937117?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01937117 being conducted?

This trial has 10 study locations across Alabama, District of Columbia, Indiana, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.